Citadel Advisors
PHIO icon

Citadel Advisors’s Phio Pharmaceuticals PHIO Stock Holding History

Citadel Advisors’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-194
Closed -$21K – 14340
2021
Q4 		$21K Buy
194
+17
+10% +$2.7K ﹤0.01% 13579
2021
Q3 		$39K Buy
177
+2
+1% +$418 ﹤0.01% 13479
2021
Q2 		$43K Buy
+175
New +$43.1K ﹤0.01% 13389

Other funds holding PHIO

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citadel Advisors's PHIO Position: Q2 2026 in Review

Citadel Advisors opened a new position in Phio Pharmaceuticals (PHIO) in Q2 2026: 47,150 shares worth $48.3K. The stake represents ﹤0.01% of the portfolio and ranks #13129 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in PHIO as recently as Q4 2024.

Citadel Advisors first reported a position in PHIO in Q2 2017 and has held it in 13 quarters since. The position peaked at $84K in Q2 2021. 24 funds tracked by Wall St. Rank hold PHIO as of Q2 2026.

  • Citadel Advisors held 47,150 shares of Phio Pharmaceuticals worth $48.3K as of Q2 2026.
  • Phio Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • Phio Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13129 holding.
  • Citadel Advisors first reported a position in Phio Pharmaceuticals in Q2 2017 and has held it in 13 quarters since.
  • Citadel Advisors's Phio Pharmaceuticals position peaked at $84K in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.